Release Summary

Hanmi and Innovent signed a strategic partnership to co-develop a novel immuno-oncology bispecific antibody. The molecule incorporates the PENTAMBODY platform developed by Beijing Hanmi.

Hanmi Pharmaceutical Co., Ltd.